Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Neogenomics Inc (NASDAQ:NEO)

9.52
Delayed Data
As of 4:00pm ET
 +0.13 / +1.39%
Today’s Change
6.90
Today|||52-Week Range
11.63
+11.03%
Year-to-Date
SECTOR
Health Services
INDUSTRY
Medical/Nursing Services
MARKET CAP
$745.1M

Company Description

NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services. It offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry, Molecular testing and Pathology consultation. The company operates through one segment: Laboratory Testing Segment. The Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Contact Information

NeoGenomics, Inc.
12701 Commonwealth Drive
Fort Myers Florida 33913
P:(239) 768-0600
Investor Relations:
(239) 325-2001

Employees

Shareholders

Other institutional37.04%
Mutual fund holders25.17%
Individual stakeholders17.25%

Top Executives

Douglas M. Van OortExecutive Chairman & Chief Executive Officer
Steven G. BrodieChief Scientific Officer & VP-Operations
Edwin Fred WeidigChief Accounting Officer & Vice President-Finance
George A. CardozaChief Financial Officer & Senior Vice President
Maher AlbitarChief Medical Officer & Senor Vice President